NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Ashley Cordova

CEOAshley Cordova

Employees

1,488

Employees1,488

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,488

Employees1,488

NVCR Key Statistics

Market cap

1.62B

Market cap1.62B

Price-Earnings ratio

-9.28

Price-Earnings ratio-9.28

Dividend yield

—

Dividend yield—

Average volume

1.28M

Average volume1.28M

High today

$14.58

High today$14.58

Low today

$14.03

Low today$14.03

Open price

$14.06

Open price$14.06

Volume

1.52M

Volume1.52M

52 Week high

$34.13

52 Week high$34.13

52 Week low

$10.87

52 Week low$10.87

NVCR News

Simply Wall St 2d

NovoCure: Evaluating the Stock's Valuation After Recent 9% Move

NovoCure (NVCR) has seen its stock shift in recent weeks, prompting investors to take a closer look at how company fundamentals line up against recent returns....

Simply Wall St 3d

New TTFields Data Presentations Might Change The Case For Investing In NovoCure

In October 2025, NovoCure announced it would present new pre-clinical and Phase 3 trial data on its Tumor Treating Fields (TTFields) therapy at the European Ass...

Analyst ratings

63%

of 8 ratings

Buy

62.5%

Hold

37.5%

Sell

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.